商业上可用的大麻素分离物,宽频谱和全频谱产品的比较药理动力学
Erin C Berthold1, Shyam H Kamble1,2, Siva Rama Raju Kanumuri1,2
1Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
European journal of drug metabolism and pharmacokinetics
|June 19, 2023
概括
含有THC的全谱大麻二醇 (CBD) 产品,与CBD分离物或广谱产品相比,显示出口服生物可用性增加. 存在的THC增强了CBD的吸收,可能增加其全身有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 大麻素科学 大麻素科学
背景情况:
- 大麻 (CBD) 产品广泛用于自我治疗.
- 有CBD油的分离,宽频 (没有THC) 或全频 (含THC<0.3%).
- 这些产品类型之间的药理动力学参数和全身暴露的差异尚未得到很好的定义.
研究的目的:
- 为了研究CBD口服吸收的药理动力学差异.
- 为了比较CBD从孤立,广谱和全谱产品的系统暴露.
主要方法:
- 老鼠接受了CBD的口服剂量作为隔离物,宽谱或全谱产品.
- 另外一项研究使用了含有0.2%THC的CBD分离物.
- 在体外测试中评估了肠道透性和THC对CBD吸收的影响.
主要成果:
- 全谱CBD显著增加了口服生物利用率 (12%在男性中,21%在女性中),而不是孤立和广谱.
- 在商业和内部全谱制剂之间没有观察到生物可用性差异.
- THC的存在增强了CBD的肠道透性,并减少了肠壁排泄.
结论:
- 在大鼠中,添加0.2%的THC显著提高了CBD口服生物可用性.
- 由于CBD暴露的增加,全谱CBD产品可能会提供增强的全身疗效.
相关概念视频
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Biopharmaceutics and Pharmacokinetics: Overview
2.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.2K
Bioavailability: Overview
2.9K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.9K
Pharmacokinetics: Overview
6.6K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
6.6K
Drug Concentration Versus Time Correlation
907
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
907
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
136
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
136


